Skip to search formSkip to main contentSkip to account menu

tecarfarin

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ATI 5923

Broader (2)

BenzoatesCoumarins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
OPTIMIZATION OF VITAMIN K ANTAGONISTS LABORATORY MONITORING AND TECARFARIN : TWO FUTURE SOLUTIONS FOR ORAL ANTICOAGULANT TREATMENT ?
  • 2018
  • Corpus ID: 261280536
Optimization of INR testing and Tecarfarin 
2018
2018
OPTIMIZATION OF VITAMIN K ANTAGONISTS LABORATORY MONITORING AND TECARFARIN : TWO FUTURE SOLUTIONS FOR ORAL ANTICOAGULANT TREATMENT ?
  • 2018
  • Corpus ID: 261280534
Optimization of INR testing and Tecarfarin 
2011
2011
Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants
Comparative pharmacokinetics of vitamin K epoxide reductase antagonists tecarfarin and warfarin were assessed before and after… 
Review
2011
Review
2011
Current and emerging therapies for stroke prophylaxis in atrial fibrillation
Atrial fibrillation (AF) increases risk of stroke fivefold. This is mainly due to cardioembolism of left atrial appendage… 
2010
2010
New anticoagulants and the future of cardiology.
2010
2010
Atrial fibrillation: Is tecarfarin a better anticoagulant than warfarin?
a phase iia trial has demonstrated that a structural analogue of warfarin is safe, tolerable, and efficacious. investigators… 
2010
2010
Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.
2010
2010
Tecarfarin: A New Oral Anticoagulant and the Characterization of its In Vitro Metabolism Using Rat, Dog, and Human Hepatocytes
Tecarfarin is a novel compound being developed for oral anticoagulation therapy for the prophylaxis and treatment of… 
2010
2010
Tecarfarin: A Novel Oral Anticoagulant and Characterization of it Pharmacokinetics, Tissue Distribution, and Mass Balance in Sprague‐Dawley Rats
Tecarfarin is a novel vitamin K epoxide reductase (VKOR) inhibitor being developed for oral anticoagulation therapy for the… 
2009
2009
Results of the EmbraceAC Trial: A Head-to-Head Comparison of Warfarin with Tecarfarin, A New Anticoagulant.
Abstract 3135 Poster Board III-72 EmbraceAC was conducted to evaluate whether tecarfarin (T) is superior to optimized… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)